Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.54 |
| ▸ | PNP | P00491 | 3/20 | 0.44 |
| ▸ | TK1 | P04183 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986800 | 0.84 | XDH (0.60) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL7513539 | 0.84 | XDH (0.51) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL4621403 | 0.83 | XDH (0.50) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL15005119 | 0.83 | XDH (0.59) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL3474052 | 0.79 | ADORA2A (0.44) | LMNASMN1; SMN2 | |
| SCHEMBL4426345 | 0.77 | XDH (0.54) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL72147 | 0.77 | XDH (0.50) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL8171998 | 0.75 | PNP (0.35) | XDHPNPMEN1KMT2ABLM | |
| SCHEMBL1825531 | 0.75 | XDH (0.51) | XDHPNPTK1MEN1KMT2A | |
| SCHEMBL1831279 | 0.74 | XDH (0.50) | XDHPNPTK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240055073-A1 | SAMPLE CONTAMINATION DETECTION OF CONTAMINATED FRAGMENTS WITH CPG-SNP CONTAMINATION MARKERS | GRAIL, LLC | 2024-02-15 | — | — | US | claimed |
| WO-2024025831-A1 | SAMPLE CONTAMINATION DETECTION OF CONTAMINATED FRAGMENTS WITH CPG-SNP CONTAMINATION MARKERS | GRAIL, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| US-11788141-B2 | MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells | PRECISION FOR MEDICINE GMBH (DE) | 2023-10-17 | — | — | US | claimed |
| US-11667973-B2 | Endosialin (CD248) as epigenetic marker for the identification of immune cells, in particular naïve CD8+ t-cells | PRECISION FOR MEDICINE GMBH (DE) | 2023-06-06 | — | — | US | claimed |
| WO-2020185681-A2 | COMPOSITIONS AND METHODS RELATED TO GOLD-MEDIATED NUCLEIC ACID HYBRIDIZATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | WO | claimed |
| EP-2189526-B1 | ANTIBODY BINDING SPECIFICALLY TO TDP-43 AGGREGATE | TOKYO METROPOLITAN INST MEDICAL SCIENCE (JP) | 2013-09-04 | — | — | EP | claimed |
| US-7521178-B1 | Method for synthesizing DNA | TAKARA BIO INC. (JP) | 2009-04-21 | — | — | US | claimed |
| US-20020142315-A1 | DNA marker for cattle growth | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2002-10-03 | — | — | US | claimed |
| EP-4381072-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF MYOTONIC DYSTROPHY | Prime Medicine, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240142451-A1 | METHODS FOR CHARACTERIZING THE IMMUNE RESPONSE OF A SUBJECT TO A DENGUE VIRUS COMPOSITION | TAKEDA VACCINES INC (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024086605-A1 | DENGUE VACCINE FORMULATION | TAKEDA VACCINES, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356925-A2 | DENGUE VACCINE FORMULATION | Takeda Vaccines, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2024081863-A1 | USE OF DENGUE VACCINE IN PREGNANT AND/OR BREASTFEEDING SUBJECTS | TAKEDA VACCINES, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240055073-A1 | SAMPLE CONTAMINATION DETECTION OF CONTAMINATED FRAGMENTS WITH CPG-SNP CONTAMINATION MARKERS | GRAIL, LLC | 2024-02-15 | — | — | US | disclosed |
| US-20040002155-A1 | Endonuclease VII cloning method | STRATAGENE | 2004-01-01 | — | — | US | disclosed |
| US-20020142315-A1 | DNA marker for cattle growth | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2002-10-03 | — | — | US | disclosed |
| EP-0639200-A1 | METHODS AND REAGENTS FOR CLEAVING AND DEPROTECTING OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-02-22 | — | — | EP | disclosed |
| WO-1993022329-A1 | METHODS AND REAGENTS FOR CLEAVING AND DEPROTECTING OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0094797-A2 | Novel cloning vehicles for polypeptide expression in microbial hosts | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1983-11-23 | — | — | EP | disclosed |
| EP-0055942-A2 | Plasmid cloning vehicles | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1982-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11788141-B2 | MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells | MVD, ENTPD5, ENTPD1 | XDH 4591/4885PNP 488/4885TK1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.